South Asian Journal of Cancer

ORIGINAL ARTICLE: BREAST CANCER
Year
: 2017  |  Volume : 6  |  Issue : 2  |  Page : 45--46

Outcome of HER2 Testing by FISH applying ASCO/CAP 2007 and 2013 guideline in IHC equivocal group of breast cancer: Experience at tertiary cancer care centre


Manoj Kumar Panigrahi1, Dushyant Kumar1, Anurag Mehta2, Kandarpa Kumar Saikia1 
1 Department of Bioengineering and Technology, Gauhati University, Guwahati, Assam, India
2 Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India

Correspondence Address:
Manoj Kumar Panigrahi
Department of Bioengineering and Technology, Gauhati University, Guwahati, Assam
India

Background and Objectives: HER2 testing guideline of ASCO/CAP for interpretation and reporting has recently been revised. The study is aimed to measure the impact of 2013 CAP guideline on equivocal HER2 test outcome (immunohistochemistry [IHC] 2+) when tested by fluorescent in situ hybridization (FISH). The study also aims at finding the frequency of polysomy and monosomy of chromosome 17. Materials and Methods: Specimens were collected in Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India. IHC was performed in every case, and FISH was performed in IHC2+ cases. Results: In final analysis includes 557 subjects on the basis of CAP guideline 2007 and CAP guideline 2013. One hundred ninety-two subjects (34.4%) were HER2 amplified according to CAP scoring 2007, and 246 subjects (44%) according to 2013 CAP scoring. Conclusions: FISH results were evaluated (IHC2 + interpreted according to CAP 2007 guideline) with both 2007 and 2013 ASCO/CAP scoring criteria, we identified significantly more HER2 positive cases as compared to cases evaluated using the 2007 criteria (P < 0.05). We also found that in breast carcinoma, HER2 status in the presence of polysomy 17 may vary with the scoring criteria used. Evaluation of FISH result using 2013 ASCO/CAP criteria means that more patients with breast cancer may be appropriate for targeted treatment with trastuzumab, potentially improving their outcome.


How to cite this article:
Panigrahi MK, Kumar D, Mehta A, Saikia KK. Outcome of HER2 Testing by FISH applying ASCO/CAP 2007 and 2013 guideline in IHC equivocal group of breast cancer: Experience at tertiary cancer care centre.South Asian J Cancer 2017;6:45-46


How to cite this URL:
Panigrahi MK, Kumar D, Mehta A, Saikia KK. Outcome of HER2 Testing by FISH applying ASCO/CAP 2007 and 2013 guideline in IHC equivocal group of breast cancer: Experience at tertiary cancer care centre. South Asian J Cancer [serial online] 2017 [cited 2017 Sep 21 ];6:45-46
Available from: http://journal.sajc.org/article.asp?issn=2278-330X;year=2017;volume=6;issue=2;spage=45;epage=46;aulast=Panigrahi;type=0